Filtered By:
Specialty: Neurology
Drug: Clopidogrel

This page shows you your search results in order of relevance. This is page number 2.

Order by Relevance | Date

Total 367 results found since Jan 2013.

Glycated albumin predicts the effect of dual and single antiplatelet therapy on recurrent stroke
Conclusions: GA could be a potential biomarker to predict the effects of dual and single antiplatelet therapy in patients with minor stroke or TIA.
Source: Neurology - March 30, 2015 Category: Neurology Authors: Li, J., Wang, Y., Wang, D., Lin, J., Wang, A., Zhao, X., Liu, L., Wang, C., Wang, Y., On behalf of the CHANCE Investigators Tags: Other cerebrovascular disease/ Stroke, Prognosis, All Cerebrovascular disease/Stroke, Infarction ARTICLE Source Type: research

Antiplatelet Strategies and Outcomes in Patients with Noncardioembolic Ischemic Stroke from a Real-World Study with a Five-Year Follow-Up
In conclusion, clopidogrel is suggested for patients with an ESRS >  3 and aspirin for patients with an ESRS ≤ 3 for the secondary prevention of noncardioembolic ischemic stroke in Chinese patients.
Source: Translational Stroke Research - December 30, 2016 Category: Neurology Source Type: research

CYP2C19 Loss-of-Function Associated with First-Time Ischemic Stroke in Non-surgical Asymptomatic Carotid Artery Stenosis During Clopidogrel Therapy
This study measures effect ofCYP2C19 genotype on ischemic stroke risk during clopidogrel therapy for asymptomatic, extracranial carotid stenosis patients. Using deidentified electronic health records, patients were selected for retrospective cohort using administrative code for carotid stenosis, availability ofCYP2C19 genotype result, clopidogrel exposure, and established patient care. Patients with intracranial atherosclerosis, aneurysm, arteriovenous malformation, prior ischemic stroke, or observation time<1 month were excluded. Dual antiplatelet therapy patients were included. Patients with carotid endarterectomy or ...
Source: Translational Stroke Research - February 21, 2021 Category: Neurology Source Type: research

Effect of addition of clopidogrel to aspirin on stroke incidence: Meta‐analysis of randomized trials
ConclusionsThis meta‐analysis demonstrates a substantial relative risk reduction in stroke by clopidogrel plus aspirin vs. aspirin alone that is consistent across different trial cohorts. Major haemorrhage is increased by dual antiplatelet therapy.
Source: International Journal of Stroke - May 22, 2013 Category: Neurology Authors: Santiago Palacio, Robert G. Hart, Lesly A. Pearce, David C. Anderson, Mukul Sharma, Lee A. Birnbaum, Oscar R. Benavente Tags: Research Source Type: research

Platelet‐Oriented Inhibition in New TIA and Minor Ischemic Stroke (POINT) Trial: Rationale and design
DiscussionAspirin is the most common antithrombotic given to patients with a stroke or transient ischemic attack, as it reduces the risk of subsequent stroke. This trial expects to determine whether more aggressive antithrombotic therapy with clopidogrel plus aspirin, initiated acutely, is more effective than aspirin alone.
Source: International Journal of Stroke - July 23, 2013 Category: Neurology Authors: S. Claiborne Johnston, J. Donald Easton, Mary Farrant, William Barsan, Holly Battenhouse, Robin Conwit, Catherine Dillon, Jordan Elm, Anne Lindblad, Lewis Morgenstern, Sharon N. Poisson, Yuko Palesch Tags: Protocols Source Type: research

Soluble CD40L Is a Useful Marker to Predict Future Strokes in Patients With Minor Stroke and Transient Ischemic Attack Brief Reports
Conclusions— Elevated sCD40L levels independently predict recurrent stroke in patients with minor stroke and transient ischemic attack. Clinical Trial Registration— URL: http://www.clinicaltrials.gov. Unique identifier: NCT00979589.
Source: Stroke - June 22, 2015 Category: Neurology Authors: Li, J., Wang, Y., Lin, J., Wang, D., Wang, A., Zhao, X., Liu, L., Wang, C., Wang, Y., on behalf of the CHANCE Investigators Tags: Secondary prevention, Risk Factors, Acute Cerebral Infarction Brief Reports Source Type: research

Association of multiple infarctions and ICAS with outcomes of minor stroke and TIA
Conclusions: The presence of multiple infarctions and ICAS were both associated with an increased risk of 90-day ischemic stroke in patients with minor stroke or TIA, while the presence of both imaging features had a combined effect. ClinicalTrials.gov identifier: NCT00979589.
Source: Neurology - March 12, 2017 Category: Neurology Authors: Pan, Y., Meng, X., Jing, J., Li, H., Zhao, X., Liu, L., Wang, D., Johnston, S. C., Wang, Y., Wang, Y., On behalf of the CHANCE Investigators Tags: All Cerebrovascular disease/Stroke, Clinical trials Observational study (Cohort, Case control) ARTICLE Source Type: research

Antiplatelet Regimen for Patients With Breakthrough Strokes While on Aspirin Brief Report
Conclusions—Among patients who experience an ischemic stroke or transient ischemic attack while on aspirin monotherapy, the addition of or a switch to another antiplatelet agent, especially in the first days after index event, is associated with fewer future vascular events, including stroke.
Source: Stroke - August 28, 2017 Category: Neurology Authors: Meng Lee, Jeffrey L. Saver, Keun-Sik Hong, Neal M. Rao, Yi-Ling Wu, Bruce Ovbiagele Tags: Secondary Prevention, Meta Analysis, Ischemic Stroke, Transient Ischemic Attack (TIA) Brief Reports Source Type: research

Dual antiplatelets reduce microembolic signals in patients with transient ischemic attack and minor stroke: subgroup analysis of CLAIR study
ConclusionsEarly dual therapy with clopidogrel and aspirin reduces microembolic signals in patients with minor ischemic stroke or transient ischemic attack, without causing significant bleeding complications.
Source: International Journal of Stroke - March 12, 2013 Category: Neurology Authors: Alexander Y. Lau, Yudong Zhao, Christopher Chen, Thomas W. Leung, Jianhui Fu, Yining Huang, Nijasri C. Suwanwela, Zhao Han, Kay Sin Tan, Disya Ratanakorn, Hugh S. Markus, Ka Sing Wong, Tags: Clinical Trial Source Type: research

Differences in ischemic and hemorrhagic recurrence rates among race‐ethnic groups in the PRoFESS secondary stroke prevention trial
ConclusionsWe found a significant difference in myocardial infarction and symptomatic intracerebral hemorrhage recurrence among different race‐ethnic groups. The risk of recurrent ischemic and hemorrhagic stroke was greater in Asians with high blood pressure.
Source: International Journal of Stroke - March 18, 2014 Category: Neurology Authors: Conrado J. Estol, Philip M. W. Bath, Philip B. Gorelick, Daniel Cotton, Renee Hebert Martin, Tags: Research Source Type: research

Effect of clopidogrel with aspirin on functional outcome in TIA or minor stroke: CHANCE substudy
Conclusions: In patients with minor stroke or TIA, the combination of clopidogrel and aspirin appears to be superior to aspirin alone in improving the 90-day functional outcome, and this is consistent with a reduction in the rate of disabling stroke in the dual antiplatelet arm. Classification of evidence: This study provides Class II evidence that for patients with acute minor stroke or TIA, clopidogrel plus aspirin compared to aspirin alone improves 90-day functional outcome (absolute reduction of poor outcome 1.70%, 95% confidence interval 0.03%–3.42%).
Source: Neurology - August 17, 2015 Category: Neurology Authors: Wang, X., Zhao, X., Johnston, S. C., Xian, Y., Hu, B., Wang, C., Wang, D., Liu, L., Li, H., Fang, J., Meng, X., Wang, A., Wang, Y., Wang, Y., For the CHANCE investigators Tags: Stroke prevention, Clinical trials Randomized controlled (CONSORT agreement), Class II, Infarction ARTICLE Source Type: research

Short-term Bleeding Events Observed with Clopidogrel Loading in Acute Ischemic Stroke Patients
Discussion: Contrary to our original hypothesis, patients with AIS receiving clopidogrel loading doses within 24 hours of symptom onset did not appear to experience a higher rate of new serious bleeding events during acute hospitalization when compared with patients who did not receive loading doses. The Platelet-Oriented Inhibition in New TIA and Minor Ischemic Stroke trial is expected to provide insight into the safety of clopidogrel loading as an acute intervention after cerebral ischemia.
Source: Journal of Stroke and Cerebrovascular Diseases - April 1, 2013 Category: Neurology Authors: Lester Y. Leung, Karen C. Albright, Amelia K. Boehme, Joseph Tarsia, Kamal R. Shah, James E. Siegler, Erica M. Jones, Gayle R. Pletsch, Timothy M. Beasley, Sheryl Martin-Schild Tags: Original Articles Source Type: research

A Comparative Study of Dual versus Monoantiplatelet Therapy in Patients with Acute Large-Artery Atherosclerosis Stroke
Background: Antiplatelet drugs are recommended for patients with acute noncardioembolic stroke. However, few randomized clinical trials have investigated the safety and efficacy of dual antiplatelet therapy for these patients. The aim of this study was to evaluate the effects of treatment with clopidogrel and aspirin (combination therapy) and aspirin alone (monotherapy) on neurologic deterioration, platelet activation, and other short-term outcomes in patients with acute large-artery atherosclerosis stroke.Materials and Methods: Altogether 574 patients with acute (≤2 days) large-artery atherosclerosis stroke were random...
Source: Journal of Stroke and Cerebrovascular Diseases - April 15, 2014 Category: Neurology Authors: Xingyang Yi, Jing Lin, Chun Wang, Biao Zhang, Wanzhang Chi Tags: Original Articles Source Type: research

Safety and Effectiveness of Intravenous Recombinant Tissue Plasminogen Activator in Acute Ischemic Stroke Patients on Aspirin and Clopidogrel (P4.284)
CONCLUSIONS: Compared with patients on no antiplatelet treatment, acute ischemic stroke patients who are actively using aspirin and clopidogrel appear to have similar risks and benefits with IV rt-PA treatment.Disclosure: Dr. Qureshi has nothing to disclose. Dr. Khan has nothing to disclose. Dr. Jahangir has nothing to disclose. Dr. Malik has nothing to disclose. Dr. Thampson has nothing to disclose. Dr. Khan has nothing to disclose. Dr. Suri has nothing to disclose. Dr. Qureshi has nothing to disclose.
Source: Neurology - April 8, 2015 Category: Neurology Authors: Qureshi, M., Khan, S., Jahangir, N., Malik, A., Thampson, M., Khan, A., Suri, M., Qureshi, A. Tags: Cerebrovascular Disease and Interventional Neurology: Acute Ischemic Stroke Care Source Type: research

Safety and efficacy of intensive vs. guideline antiplatelet therapy in high‐risk patients with recent ischemic stroke or transient ischemic attack: rationale and design of the Triple Antiplatelets for Reducing Dependency after Ischaemic Stroke (TARDIS) trial (ISRCTN47823388)
DiscussionThe trial has recruited more than 50% of its target sample size (latest number: 2399) and is running in 104 sites in 4 countries. One‐third of patients presented with a transient ischemic attack.
Source: International Journal of Stroke - June 16, 2015 Category: Neurology Tags: Protocol Source Type: research